Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Study of an Optimized Chemotherapy Followed by Maintenance With Bevacizumab Strategy With or Without Erlotinib in Unresectable Metastatic Colorectal Cancer. DREAM OPTIMOX 3. C04-2

Trial Profile

Phase III Study of an Optimized Chemotherapy Followed by Maintenance With Bevacizumab Strategy With or Without Erlotinib in Unresectable Metastatic Colorectal Cancer. DREAM OPTIMOX 3. C04-2

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs Erlotinib (Primary) ; Bevacizumab; Capecitabine; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms DREAM; GERCOR DREAM
  • Most Recent Events

    • 20 Jan 2018 Results of a post-hoc analysis evaluating clinical outcomes according to KRAS mutational status and Primary tumor sidedness presented at the 2018 Gastrointestinal Cancers Symposium
    • 07 Jun 2016 Results of health-related quality of life data presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 13 Oct 2015 Results (n=452) published in the Lancet Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top